Furthermore, an increased expression of senescent and exhaustion markers, as programmed death (PD)-1/programmed death-ligand (PD-L)1, cytotoxic T-lymphocyte antigen (CTLA-4) and T cell immunoreceptor with Ig and ITIM domains (TIGIT) has been detected in BM immune-microenvironment of MM patients, leading to the development of monoclonal antibodies (mAbs) targeting these molecules. The gene discussed is CD274; the disease is Miyoshi myopathy.